Company name:
Zoetis Inc
-
IPO SHARE PRICE:$26.00
-
IPO DATE:February 01, 2013
-
TICKER:ZTS
-
MAIN STOCK EXCHANGE:New York Stock Exchange
-
CURRENT HQ LOCATION:10 Sylvan Way Parsippany New Jersey 07054
-
FISCAL YEAR END:December 31
-
INCORPORATION JURISDICTION:None
-
ORGANIZED AS THE FOLLOWING LEGAL TYPE:Corporation
-
Investor Relations Webpage:Coming soon!
-
TAX RATE:USA federal corporate nominal income tax rate is 21%
Short Description
Zoetis Inc
We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com
Statement of Cash Flow
(USD in thousand)
Selected Year:
31-Dec
2020
2020
OPERATING ACTIVITIES
Cash received and spent on operating activites of business — buying materials, paying salaries, receiving payments from clients, etc
62.3% -
Net income (loss) before allocation to non-controlling interests
16.8% -
Depreciation and amortization
5.6% -
Accounts payable
4.0% -
Provision for losses on inventory
3.5% -
Other liabilities
2.8% -
Accounts receivable
2.2% -
Stock-based compensation
1.6% -
Asset write-offs and impairments
0.6% -
Other tax accounts net
0.4% -
Other non-cash adjustments
0.1% -
Employee benefit plan contribution from Pfizer Inc
SOURCEs
16.8%
3.5%
5.6%
4.0%
62.3%
100 %
0%
USES
80.9%
13.2%
13.2% -
Inventory
2.6% -
Other assets
2.4% -
Deferred income taxes
0.7% -
(Gain) loss on sale of assets
0.2% -
Loss on treasury locks
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) before allocation to non-controlling interests | $1,424,000 | $1,500,000 | $1,636,000 | $1,636,000 | $1,432,000 | ||||||||
|
Depreciation and amortization
|
308,000 | 412,000 | 441,000 | 441,000 | 436,000 | ||||||||
|
Stock-based compensation
|
53,000 | 67,000 | 59,000 | 59,000 | 52,000 | ||||||||
|
Provision for losses on inventory
|
54,000 | 68,000 | 105,000 | 105,000 | 196,000 | ||||||||
|
Deferred income taxes
|
(112,000) | (79,000) | (62,000) | (62,000) | (88,000) | ||||||||
|
Asset write-offs and impairments
|
4,000 | 7,000 | 43,000 | 43,000 | 124,000 | ||||||||
|
(Gain) loss on sale of assets
|
(42,000) | (20,000) | (19,000) | (19,000) | - | ||||||||
|
Loss on treasury locks
|
- | - | (6,000) | (6,000) | - | ||||||||
|
Foreign currency loss related to Venezuela Revaluation excluding impact on cash
Foreign currency loss related to Venezuela Revaluation excluding impact on cash
|
- | - | - | - | - | ||||||||
|
Non-cash restructuring costs
|
- | - | - | - | - | ||||||||
|
Employee benefit plan contribution from Pfizer Inc
|
3,000 | 3,000 | 3,000 | 3,000 | 4,000 | ||||||||
|
Other non-cash adjustments
|
(14,000) | (12,000) | 11,000 | 11,000 | 8,000 | ||||||||
|
Accounts receivable
|
(67,000) | (69,000) | 74,000 | 74,000 | 20,000 | ||||||||
|
Inventory
|
61,000 | (104,000) | (346,000) | (346,000) | (208,000) | ||||||||
|
Other assets
|
(42,000) | (51,000) | (68,000) | (68,000) | 328,000 | ||||||||
|
Accounts payable
|
37,000 | (10,000) | 147,000 | 147,000 | 392,000 | ||||||||
|
Other tax accounts net
|
67,000 | (8,000) | 17,000 | 17,000 | (384,000) | ||||||||
|
Other liabilities
|
56,000 | 91,000 | 91,000 | 91,000 | 560,000 | ||||||||
| Net cash provided by (used in) operating activities | $1,790,000 | $1,795,000 | $2,126,000 | $2,126,000 | $2,872,000 |
Selected Year:
31-Dec
2020
2020
INVESTING ACTIVITIES
Cash spent on acquiring plant, equipment and other businesses, cash recei0 from sale of plant, equipment and subsidiaries as well cash parked temporarily in different securities - government bonds typically
3.5% -
Sale of assets
SOURCEs
96.5%
3.5%
100 %
0%
USES
76.4%
19.1%
4.6%
76.4% -
Capital expenditures
19.1% -
Other acquisitions
4.6% -
Net proceeds from swaps designated as net investment hedges
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Maturities of investment securities
|
28,000 | 101,000 | - | - | - | ||||||||
|
Capital expenditures
|
(338,000) | (460,000) | (453,000) | (453,000) | (608,000) | ||||||||
|
(Purchase) sale of property plant and equipment
|
- | - | - | - | - | ||||||||
|
Sale of assets
|
56,000 | 21,000 | 21,000 | 21,000 | - | ||||||||
|
Acquisitions
|
- | - | - | - | - | ||||||||
|
Acquisition of Abaxis
|
(1,884,000) | - | - | - | - | ||||||||
|
Acquisition of Abbott Animal Health
|
- | - | - | - | - | ||||||||
|
Acquisition of Pharmaq
|
- | - | - | - | - | ||||||||
|
Milestone payment related to previously acquired intangibles
Milestone payment related to previously acquired intangibles
|
- | - | - | - | - | ||||||||
|
Other acquisitions
|
(114,000) | (195,000) | (113,000) | (113,000) | (20,000) | ||||||||
|
Net proceeds from swaps designated as net investment hedges
Net proceeds from swaps designated as net investment hedges
|
- | 37,000 | (27,000) | (27,000) | (76,000) | ||||||||
|
Other investing activities
|
(7,000) | (8,000) | - | - | - | ||||||||
| Net cash provided by (used in) investing activities | ($2,259,000) | ($504,000) | ($572,000) | ($572,000) | ($708,000) |
Selected Year:
31-Dec
2020
2020
FINANCING ACTIVITIES
Items in this group are concerned with borrowing funds, repaying debt, issuing equity, buying back shares, etc.
97.9% -
Issuance of Senior Notes
1.6% -
Issuance of common stock upon exercise of stock options and excess tax benefits
0.3% -
Short-term borrowing (repayment)
0.2% -
Acquisition of non-controlling interests
SOURCEs
0.0%
97.9%
100 %
0%
USES
9.7%
30.0%
39.5%
19.7%
39.5% -
Repayment of long-term borrowing
30.0% -
Dividends paid
19.7% -
Stock repurchases
0.9% -
Debt issuance costs
0.2% -
Contingent consideration payment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Issuance of common stock upon exercise of stock options and excess tax benefits
Issuance of common stock upon exercise of stock options and excess tax benefits
|
19,000 | 7,000 | 20,000 | 20,000 | 80,000 | ||||||||
|
Short-term borrowing
|
- | - | - | - | - | ||||||||
|
Short-term borrowing (repayment)
|
8,000 | (9,000) | 4,000 | 4,000 | 12,000 | ||||||||
|
Repayment of short-term borrowing
|
- | - | - | - | - | ||||||||
|
Issuance of Senior Notes
|
1,485,000 | - | 1,240,000 | 1,240,000 | - | ||||||||
|
Repayment of Pharmaq debt
|
- | - | - | - | - | ||||||||
|
Repayment of long-term borrowing
|
- | - | (500,000) | (500,000) | (2,000,000) | ||||||||
|
Debt issuance costs
|
- | - | (12,000) | (12,000) | - | ||||||||
|
Acquisition of non-controlling interests
|
(26,000) | - | 3,000 | 3,000 | - | ||||||||
|
Consideration paid to Pfizer Inc in connection with the separation
Consideration paid to Pfizer Inc in connection with the separation
|
- | - | - | - | - | ||||||||
|
Contingent consideration payment
|
(12,000) | (9,000) | (2,000) | (2,000) | (8,000) | ||||||||
|
Dividends paid
|
(243,000) | (314,000) | (380,000) | (380,000) | (380,000) | ||||||||
|
Stock repurchases
|
(698,000) | (626,000) | (250,000) | (250,000) | - | ||||||||
|
Net financing activities with Pfizer
|
- | - | - | - | - | ||||||||
|
Other net financing activities with Pfizer Inc
|
- | - | - | - | - | ||||||||
| Net cash provided by (used in) financing activities | $533,000 | ($951,000) | $123,000 | $123,000 | ($2,388,000) |
Selected Year:
31-Dec
2020
2020
NET CHANGE IN CASH
Grand Total for sum of cash flows coming from operations, investing and financing
$1,670,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents - Beginning of period | $1,564,000 | $1,602,000 | $1,934,000 | - | $14,616,000 | ||||||||
| Effect of changes in foreign exchange rates on cash | (26,000) | (8,000) | (7,000) | - | 24,000 | ||||||||
| (Decrease) increase in cash and cash equivalents | 38,000 | 332,000 | 1,670,000 | - | (200,000) | ||||||||
| Cash and equivalents - End of period | $1,602,000 | $1,934,000 | $3,604,000 | - | $14,416,000 |